glycoprotein E + CpG 1018

**glycoprotein E + CpG 1018** is a combination vaccine candidate comprising recombinant varicella-zoster virus glycoprotein E antigen and the CpG 1018 adjuvant. CpG 1018 is a proprietary synthetic oligodeoxynucleotide that functions as a Toll-like receptor 9 (TLR9) agonist, designed to boost both humoral and cell-mediated immunity. The vaccine is under development primarily as a shingles (herpes zoster) vaccine, aiming to induce robust anti-gE IgG antibody responses and gE-specific CD4+ T-cell immunity, with alum sometimes included as an additional adjuvant. Dynavax is developing this vaccine as Z-1018 for the prevention of herpes zoster, with trials comparing its efficacy and safety to approved zoster recombinant vaccines[4][3][1].

Brand names

Z-1018Z1018Z 1018

Other names

glycoprotein E plus CpG 1018gE + CpG 1018